CAVA Group vs Yum! Brands: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CAVA Group, Inc. (CAVA)

Q3 202615 Jul – 12 Aug 2026

▲3▼1

CAVA beats Q2 estimates as cyclospora fears fade, analyst upgrade lifts stock

Morgan Stanley upgrade Morgan Stanley upgraded CAVA to overweight, calling it one of the strongest fundamental stories in restaurants. An upgrade from a major bank signals confidence in the business and draws new investor attention, pushing the stock up.
This is a new analyst endorsement that directly lifted CAVA shares and frames the bull case.
FDA cyclospora outbreak investigation The FDA investigated a cyclospora outbreak that hit the fast-casual sector, dragging CAVA and Sweetgreen down. Health scares scare customers away and raise uncertainty, so the stock fell until the issue eased.
This was the main negative force on CAVA during the period and explains the earlier drop.
Q2 earnings beat and guidance affirmed CAVA beat second-quarter revenue and earnings estimates, with same-restaurant sales up 9% and adjusted EBITDA up 30%. It opened 17 net new restaurants and affirmed full-year guidance, showing the growth story is intact and pushing the stock sharply higher.
The earnings beat is the biggest new positive catalyst and confirms the company's fundamentals.
Cyclospora headwinds moderating Jefferies said quarter-to-date trends were better than feared, with cyclospora-related weakness bottoming in mid-to-late July before same-restaurant sales recovered toward mid-single-digit growth. Fears easing removes a cloud over the stock and supports the rebound.
This explains why the earlier negative health-scare pressure reversed and the stock jumped.

July 202615 Jul – 12 Aug 2026

▲3▼1

CAVA beats Q2 estimates as cyclospora fears fade, analyst upgrade lifts stock

Morgan Stanley upgrade Morgan Stanley upgraded CAVA to overweight, calling it one of the strongest fundamental stories in restaurants. An upgrade from a major bank signals confidence in the business and draws new investor attention, pushing the stock up.
This is a new analyst endorsement that directly lifted CAVA shares and frames the bull case.
FDA cyclospora outbreak investigation The FDA investigated a cyclospora outbreak that hit the fast-casual sector, dragging CAVA and Sweetgreen down. Health scares scare customers away and raise uncertainty, so the stock fell until the issue eased.
This was the main negative force on CAVA during the period and explains the earlier drop.
Q2 earnings beat and guidance affirmed CAVA beat second-quarter revenue and earnings estimates, with same-restaurant sales up 9% and adjusted EBITDA up 30%. It opened 17 net new restaurants and affirmed full-year guidance, showing the growth story is intact and pushing the stock sharply higher.
The earnings beat is the biggest new positive catalyst and confirms the company's fundamentals.
Cyclospora headwinds moderating Jefferies said quarter-to-date trends were better than feared, with cyclospora-related weakness bottoming in mid-to-late July before same-restaurant sales recovered toward mid-single-digit growth. Fears easing removes a cloud over the stock and supports the rebound.
This explains why the earlier negative health-scare pressure reversed and the stock jumped.

Latest15 Jul – 12 Aug 2026

▲3▼1

CAVA beats Q2 estimates as cyclospora fears fade, analyst upgrade lifts stock

Morgan Stanley upgrade Morgan Stanley upgraded CAVA to overweight, calling it one of the strongest fundamental stories in restaurants. An upgrade from a major bank signals confidence in the business and draws new investor attention, pushing the stock up.
This is a new analyst endorsement that directly lifted CAVA shares and frames the bull case.
FDA cyclospora outbreak investigation The FDA investigated a cyclospora outbreak that hit the fast-casual sector, dragging CAVA and Sweetgreen down. Health scares scare customers away and raise uncertainty, so the stock fell until the issue eased.
This was the main negative force on CAVA during the period and explains the earlier drop.
Q2 earnings beat and guidance affirmed CAVA beat second-quarter revenue and earnings estimates, with same-restaurant sales up 9% and adjusted EBITDA up 30%. It opened 17 net new restaurants and affirmed full-year guidance, showing the growth story is intact and pushing the stock sharply higher.
The earnings beat is the biggest new positive catalyst and confirms the company's fundamentals.
Cyclospora headwinds moderating Jefferies said quarter-to-date trends were better than feared, with cyclospora-related weakness bottoming in mid-to-late July before same-restaurant sales recovered toward mid-single-digit growth. Fears easing removes a cloud over the stock and supports the rebound.
This explains why the earlier negative health-scare pressure reversed and the stock jumped.

Yum! Brands Inc (YUM)

Q3 202617 Jun – 7 Aug 2026

▲3▼1

Yum sells Pizza Hut, buys back stock, but Taco Bell outbreak hits sales

Pizza Hut sale and $4B buyback Yum is selling Pizza Hut for about $2.3–2.7 billion and using $4 billion to buy back its own stock. This simplifies the company to focus on KFC and Taco Bell and returns cash to shareholders.
This is a major strategic move that reshapes the company and directly affects the stock.
Cyclospora outbreak hits Taco Bell sales A nationwide cyclospora outbreak linked to Taco Bell lettuce sickened thousands, caused a nearly 19% one-day traffic drop, and drove July U.S. same-store sales down 2%. Yum warned of much lower third-quarter margins.
This is a major negative event that hurt sales and profits and remains a risk.
Q2 profit jumps 128% Yum's second-quarter profit jumped 128% to $853 million, beating expectations. This shows strong underlying profitability despite the outbreak.
Strong earnings are a key positive driver for the stock.
Taco Bell sales recovering, stock rises 4% Taco Bell sales are recovering from the outbreak, and the stock rose about 4% on that news. However, the outbreak's profit impact remains a risk.
Recovery news lifted the stock, showing investor confidence in a rebound.

July 202617 Jun – 7 Aug 2026

▲3▼1

Yum sells Pizza Hut, buys back stock, but Taco Bell outbreak hits sales

Pizza Hut sale and $4B buyback Yum is selling Pizza Hut for about $2.3–2.7 billion and using $4 billion to buy back its own stock. This simplifies the company to focus on KFC and Taco Bell and returns cash to shareholders.
This is a major strategic move that reshapes the company and directly affects the stock.
Cyclospora outbreak hits Taco Bell sales A nationwide cyclospora outbreak linked to Taco Bell lettuce sickened thousands, caused a nearly 19% one-day traffic drop, and drove July U.S. same-store sales down 2%. Yum warned of much lower third-quarter margins.
This is a major negative event that hurt sales and profits and remains a risk.
Q2 profit jumps 128% Yum's second-quarter profit jumped 128% to $853 million, beating expectations. This shows strong underlying profitability despite the outbreak.
Strong earnings are a key positive driver for the stock.
Taco Bell sales recovering, stock rises 4% Taco Bell sales are recovering from the outbreak, and the stock rose about 4% on that news. However, the outbreak's profit impact remains a risk.
Recovery news lifted the stock, showing investor confidence in a rebound.

Latest17 Jun – 7 Aug 2026

▲3▼1

Yum's Pizza Hut exit and Taco Bell recovery shape the story

Pizza Hut sale completed Yum finished selling Pizza Hut in mainland China for $1.2 billion, part of a $2.7 billion plan to exit the brand. This simplifies Yum, brings in cash, and lets it focus on KFC and Taco Bell, which supports the stock.
This is a major new step in Yum's restructuring that directly affects its future earnings and cash returns.
Taco Bell sales recovering Yum said Taco Bell's sales hit from the parasite outbreak are easing, with a steady recovery since mid-July. Investors grew more confident the hit is temporary, sending the stock up about 4% on the news.
This is new information about the outbreak's impact fading, which is key to Yum's largest growth brand.
Taco Bell sales still down Taco Bell's U.S. same-store sales fell 2% in July due to the food-safety scare, and Yum warned third-quarter margins will be much lower than last quarter. This shows the outbreak is still hurting profits and keeps pressure on the stock.
This is the main counterweight: despite recovery, the outbreak continues to drag on sales and margins.
Strong Q2 earnings Yum's second-quarter profit jumped 128% to $853 million, beating expectations, and the company reaffirmed its long-term growth targets. This shows the core business is healthy and supports the stock price.
This is a new earnings report that gives a clear picture of Yum's financial health and future outlook.

24 Jun – 21 Jul 2026

▼2▲1

Yum sells Pizza Hut, but Taco Bell lettuce outbreak hits traffic and sales

Pizza Hut sale sharpens focus on KFC and Taco Bell Yum is selling Pizza Hut for about $2.3 billion and authorizing a $4 billion buyback. This simplifies the company, giving it cash to return to shareholders and focus on its stronger brands, KFC and Taco Bell. That supports the stock price by improving growth prospects and capital returns.
This is a major strategic move that directly affects YUM's business mix and shareholder value.
Cyclospora outbreak linked to Taco Bell lettuce A nationwide cyclospora outbreak tied to shredded lettuce served at Taco Bell has sickened thousands. Taco Bell removed fresh produce items, disrupting its menu and supply. This hurts customer trust and sales, pushing the stock down as investors worry about the impact on the key brand.
This is a new, material event that directly threatens Taco Bell's sales and reputation.
Taco Bell traffic plunges after outbreak Foot traffic at Taco Bell fell nearly 19% on July 17 compared to a typical Friday, and analysts cut same-store sales estimates. Since Taco Bell is now Yum's main growth engine after the Pizza Hut sale, this slowdown weighs heavily on the stock price.
This quantifies the negative impact on Yum's most important brand, directly affecting earnings expectations.